Health Care • Biotechnology: Pharmaceutical Preparations
$3.09 ▲ +0.05
(+1.65%)
MKT CAP: $26.5M • VOL: 60.2K
52W L $3 52W H $13
ROARABLE / RQD
D- • 40/100
PIOTROSKI
1 / 9
BCTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-07-31 | FY 2024
FILED 2024-07-31 | FY 2023
FILED 2023-07-31 |
|---|---|---|---|
| Revenue (Total Sales) | $76.2M | $93.3M | $65.2M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$27.2M | -$33.3M | -$23.3M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$26.3M | -$4.8M | -$20.3M |
| EBITDA (Normalized) | — | -$33.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$28.2M | -$24.1M | -$23.7M |
| Capital Expenditures (CapEx) | — | $456.8K | — |
| Free Cash Flow (FCF) | -$28.2M | -$24.6M | -$23.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | $29.9M | $5.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | — | — | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BCTX.